Lupin divests women's health specialty biz in US to Evofem Biosciences

Q: How long will it take to read this news story?

The story "Lupin divests women&#039;s health specialty biz in US to Evofem Biosciences" has 502 words across 18 sentences, which will take approximately 3 - 5 minutes for the average person to read.

Q: Which news outlet covered this story?

The story "Lupin divests women&#039;s health specialty biz in US to Evofem Biosciences" was covered 2 days ago by Business Standard, a news publisher based in India.

Q: How trustworthy is 'Business Standard' news outlet?

Business Standard is a fully independent (privately-owned) news outlet established in 1975 that covers mostly business and finance news. The outlet is headquartered in India and publishes an average of 237 news stories per day. It's most recent story was published 2 hours ago.

Q: What do people currently think of this news story?

The sentiment for this story is currently Neutral, indicating that people are not responding positively or negatively to this news.

Q: How do I report this news for inaccuracy?

You can report an inaccurate news publication to us via our contact page. Please also include the news #ID number and the URL to this story.<ul><li>News ID: #21627753</li><li>URL: https://beamstart.com/news/lupin-divests-womens-health-specialty-172104538927</li></ul>

Business Standard Logo Business Standard 2d ago

Lupin divests women's health specialty biz in US to Evofem Biosciences - Business Standard

Quick Summary:

We can now fully leverage our commercial infrastructure, maximise our strong physician relationships, and re-launch an asset with tremendous growth potential,” said Saundra Pelletier, chief executive officer of Evofem.

In India, growth had been subdued due to the discontinuation of in-licensed brands (contribution down from 15 per cent in FY23 to 11 per cent in Q4FY24)."Going ahead, management is targeting 10 per cent year-on-year growth in India in FY25.

The launch of generic Spiriva in the US, softer raw material costs, and export incentives have helped Lupin improve margins by a robust 870 basis points (bps) year-on-year to 19 per cent in FY24.